Log In
Print
BCIQ
Print
Print this Print this
 

obiltoxaximab (Anthim) (ETI-204)

  Manage Alerts
Collapse Summary General Information
Company Elusys Therapeutics Inc.
DescriptionHigh-affinity humanized mAb against the Bacillus anthracis protective antigen that inhibits binding of anthrax toxins
Molecular Target Bacillus anthracis protective antigen
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationAnthrax
Indication DetailsTreat and prevent anthrax infection; Treat anthrax infection
Regulatory Designation

U.S. - Fast Track (Treat and prevent anthrax infection);
U.S. - Orphan Drug (Treat and prevent anthrax infection)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today